Your browser doesn't support javascript.
Antibody Response 3 Months After 2-Dose SARS-CoV-2 mRNA Vaccination in Patients With Inflammatory Bowel Disease.
Tsipotis, Evangelos; Frey, Sarah; Connolly, Caoilfhionn; Werbel, William A; Chowdhury, Reezwana; Dudley-Brown, Sharon; Melia, Joanna M; Parian, Alyssa M; Truta, Brindusa; Yu, Huimin; Selaru, Florin M; Segev, Dorry L; Lazarev, Mark.
  • Tsipotis E; Hopkins IBD Center, Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Frey S; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Connolly C; Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Werbel WA; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Chowdhury R; Hopkins IBD Center, Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Dudley-Brown S; Hopkins IBD Center, Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Melia JM; Hopkins IBD Center, Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Parian AM; Hopkins IBD Center, Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Truta B; Hopkins IBD Center, Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Yu H; Hopkins IBD Center, Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Selaru FM; Hopkins IBD Center, Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Segev DL; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Lazarev M; Hopkins IBD Center, Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Am J Gastroenterol ; 117(5): 798-801, 2022 05 01.
Article in English | MEDLINE | ID: covidwho-1835980
ABSTRACT

INTRODUCTION:

The response to SARS-CoV-2 vaccination of patients with inflammatory bowel disease (IBD) on immune-modifying therapies requires further investigation because previous studies indicate that patients on immune therapy might have decreased antibody concentrations.

METHODS:

We present the antireceptor binding domain antibody response over a period of 3 months in 217 patients with IBD who completed standard 2-dose SARS-CoV-2 mRNA vaccine series.

RESULTS:

Almost all (98.6%) IBD vaccine recipients had a positive antireceptor binding domain antibody response at least 3 months after vaccination. Decreased antibody titers at 3 months were seen in a subset of patients on antitumor necrosis factor-alpha. Approximately 10% of the participants with high-titer antibodies at 1 month had a decrease to low-positive titers at 3 months, which was mostly observed in those on combination therapy and antitumor necrosis factor-alpha monotherapy.

DISCUSSION:

Larger longitudinal studies are required to define the response in IBD population and its clinical impact.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Inflammatory Bowel Diseases / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Am J Gastroenterol Year: 2022 Document Type: Article Affiliation country: Ajg.0000000000001668

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Inflammatory Bowel Diseases / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Am J Gastroenterol Year: 2022 Document Type: Article Affiliation country: Ajg.0000000000001668